Department of Public Health, Section of General Practice, University of Aarhus, Aarhus, Denmark
MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.
Diabetes Care. 2014 Jul;37(7):2015-23. doi: 10.2337/dc13-1544. Epub 2014 May 1.
To determine the benefit of multifactorial treatment on microvascular complications among people with type 2 diabetes detected by screening.
This study was a multicenter cluster randomized controlled trial in primary care with randomization at the practice level. In four centers in Denmark; Cambridge, U.K.; the Netherlands; and Leicester, U.K., 343 general practices participated in the trial. Eligible for follow-up were 2,861 of the 3,057 people with diabetes detected by screening included in the original trial. Biomedical data on nephropathy were collected in 2,710 (94.7%) participants, retinal photos in 2,190 (76.6%), and questionnaire data on peripheral neuropathy in 2,312 (80.9%). The prespecified microvascular end points were analyzed by intention to treat. Results from the four centers were pooled using fixed-effects meta-analysis.
Five years after diagnosis, any kind of albuminuria was present in 22.7% of participants in the intensive treatment (IT) group and in 24.4% in the routine care (RC) group (odds ratio 0.87 [95% CI 0.72-1.07]). Retinopathy was present in 10.2% of the IT group and 12.1% of the RC group (0.84 [0.64-1.10]), and severe retinopathy was present in one patient in the IT group and seven in the RC group. Neuropathy was present in 4.9% and 5.9% (0.95 [0.68-1.34]), respectively. Estimated glomerular filtration rate increased between baseline and follow-up in both groups (4.31 and 6.44 mL/min, respectively).
Compared with RC, an intervention to promote target-driven, intensive management of patients with type 2 diabetes detected by screening was not associated with significant reductions in the frequency of microvascular events at 5 years.
确定在通过筛查发现的 2 型糖尿病患者中,多因素治疗对微血管并发症的益处。
这是一项在初级保健中进行的多中心集群随机对照试验,在丹麦的 4 个中心、英国的剑桥和荷兰以及英国的莱斯特的 343 个普通诊所进行了随机分组。在最初试验中包括的 3057 名通过筛查发现的糖尿病患者中,有 2861 名符合随访条件。在 2710 名(94.7%)参与者中收集了关于肾病的生物医学数据,在 2190 名(76.6%)参与者中收集了视网膜照片,在 2312 名(80.9%)参与者中收集了周围神经病变的问卷调查数据。根据意向治疗分析了预先规定的微血管终点。使用固定效应荟萃分析对来自四个中心的结果进行了汇总。
在诊断后 5 年,强化治疗(IT)组中任何类型的白蛋白尿的发生率为 22.7%,常规治疗(RC)组为 24.4%(优势比 0.87 [95%置信区间 0.72-1.07])。IT 组中有 10.2%的患者存在视网膜病变,RC 组中有 12.1%的患者存在视网膜病变(0.84 [0.64-1.10]),IT 组中有 1 名患者出现严重视网膜病变,RC 组中有 7 名患者出现严重视网膜病变。神经病变分别为 4.9%和 5.9%(0.95 [0.68-1.34])。两组的估计肾小球滤过率均在基线和随访之间增加(分别为 4.31 和 6.44 mL/min)。
与 RC 相比,针对通过筛查发现的 2 型糖尿病患者进行以目标为导向的强化管理的干预措施,在 5 年内并未显著降低微血管事件的发生频率。